IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance
SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation.
NTS071 is an oral small molecule allosteric reactivator targeting p53 Y220C with a novel scaffold. It selectively binds to the p53 Y220C mutant protein, improving its thermal stability, thereby enhancing the mutant protein's ability to bind with DNA and restoring its transcriptional activity as well as tumor-suppressing function.
NTS071 was discovered by leveraging Nutshell's proprietary AI driven allosteric small molecule drug discovery platform ALLOSTAR™. NTS071 demonstrated potential Best-in-Class preclinical properties for its target. NTS071 achieved a picomolar-level biochemical activity which is 20 folds more potent than the competitive compound PC14586. Additionally, NTS071 shows better stability in both liver microsomes and hepatocytes across different species and exhibits lower in vivo clearance rates and higher oral exposure s in preclinical PK studies across all tested species compared to PC14586. NTS071 has relatively lower plasma protein binding and higher free fraction than PC14586, which is beneficial for in vivo efficacy. NTS071 also addresses the CYP3A4 inhibition issue of PC14586, presenting lower risks for potential drug – drug interactions. NTS071 further displays a large safety window by exhibiting an overall good safety profile in non-clinical toxicology studies.
NTS071 exhibited dose-dependent in vivo anti-tumor activity in multiple CDX and PDX models harboring p53 Y220C mutation, spanning a number of different cancer types, including ovarian cancer, lung cancer, gastric cancer, breast cancer, head and neck cancer, esophageal cancer, pancreatic cancer, and bladder cancer, etc. Therefore, NTS071 has the potential to be a tumor-agnostic therapy for patients carrying p53 Y220C mutation. Compared to PC14586, NTS071 has shown significantly lower effective doses or better efficacy at the same dose level in all comparative preclinical in vivo studies, implying that NTS071 may overcome the limitation of its competitor that has a higher dose requirement, thereby potentially achieving better therapeutic effects. NTS071 is anticipated to initiate Phase 1 clinical trial in second half of 2025 and expected to benefit patients with solid tumors harboring this mutation.
p53 Y220C mutation is widespread in various solid tumors. Studies show that there are 125,000 to 150,000 new cases worldwide annually, representing a significant market potential. Enriched with years of accumulated experience with its proprietary computation-based allosteric drug development technology and breakthrough innovation capabilities at Nutshell Therapeutics, NTS071 has the potential to stand out among peer products and become the most competitive drug molecule for this target.
The NTS071 Poster presented at the EORTC-NCI-AACR (ENA) 2024 conference can be accessed here: http://allonutshell.com/images/109_Nutshell-NTS071-ENA-2024-Poster.pdf
About Nutshell
Nutshell Therapeutics ( http://www.allonutshell.com/ ) is an innovative biotech company developing small molecule drugs for historically challenging targets employing allosteric mechanisms. Founded by Professor Zhang Jian, one of the leading figures in the allosteric drug discovery field globally, the company has established an integrated R&D platform with diverse dry and wet lab functions and has focused intensely on allosteric small - molecule drug discovery and development for many years. The company has successfully raised more than US$75 million from various well-known venture capitals.
View original content to download multimedia: https://www.prnewswire.com/news-releases/ind-application-for-nts071-nutshell-therapeutics-p53-y220c-allosteric-reactivator-received-us-fda-clearance-302445533.html
SOURCE Nutshell Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Cognex Introduces OneVision: A Breakthrough Cloud Platform for AI-Powered Machine Vision
New Training Environment Delivers Scalable Automation and Solves Key Barriers to Industrial AI Adoption NATICK, Mass., June 10, 2025 /PRNewswire/ -- Cognex Corporation (NASDAQ: CGNX), the global technology leader in industrial machine vision, today announced the upcoming full launch of OneVision™, a cloud-based platform that will transform how manufacturers build, train, and scale AI-powered vision manufacturers build, train, and scale AI-powered vision applications. "OneVision is the result of nearly a decade of industrial AI innovation at Cognex. By combining our advanced AI technology with excellent customer experience, we continue to unlock new possibilities for our customers," said Carl Gerst, Executive Vice President of Vision and ID Products at Cognex. "We're simplifying the entire application development process; helping our customers move faster, scale more efficiently, and maximize the value of their automation investments." Designed for the demands of global manufacturing, OneVision tackles the most common barriers to wide-scale deployment of AI-powered machine vision: Long development cycles and steep learning curves: An intuitive interface with guided workflows allows teams of all skill levels to shorten setup time from months to minutes. Expensive infrastructure investments: Cloud-based delivery eliminates the need for additional hardware, lowering upfront costs and maximizing ROI. Lack of integration and disconnected operations: A unified platform brings tools, data, and workflows together to streamline collaboration, leverage shared work, and accelerate deployment across devices, lines, and locations. Inconsistent performance across sites: Centralized development combined with local customization ensures standardization while providing flexibility for site-specific requirements. With the OneVision software platform, Cognex expands its industry-leading portfolio of machine vision products, unlocking new applications, accelerating AI adoption, and allowing users to solve complex vision tasks faster, more reliably, and at scale. OneVision is currently available to select customers on the In-Sight® 3800 and 8900 vision systems and will be released on additional Cognex products in early 2026. and will be released on additional Cognex products in early 2026. About Cognex Corporation For over 40 years, Cognex has been making advanced machine vision easy, paving the way for manufacturing and distribution companies to get faster, smarter, and more efficient through automation. Innovative technology in our vision sensors and systems solves critical manufacturing and distribution challenges, providing unparalleled performance for industries from automotive to consumer electronics to packaged goods. Cognex makes these tools more capable and easier to deploy thanks to a longstanding focus on AI, helping factories and warehouses improve quality and maximize efficiency without needing highly technical expertise. We are headquartered near Boston, USA, with locations in over 30 countries and more than 30,000 customers worldwide. Learn more at IR ContactGreer AvivHead of Investor RelationsCognex Corporationir@ Media ContactJeremy SaccoSenior Manager, Global Content MarketingCognex Corporationpr@ SOURCE Cognex Corporation Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2025
NEW YORK, June 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of May 31, 2025, an increase of $1.1 billion from assets under management of $87.5 billion at April 30, 2025. The increase was due to market appreciation of $1.3 billion, partially offset by distributions of $150 million and net outflows of $88 million. Assets Under Management (unaudited) ($ in millions) AUM Net MarketAUM By investment vehicle: 4/30/2025 Flows App/(Dep) Distributions 5/31/2025 Institutional Accounts: Advisory $19,937 $10 $352 - $20,299 Subadvisory 14,091 (19) 306 (57) 14,321 Total Institutional Accounts 34,028 (9) 658 (57) 34,620 Open-end Funds 42,210 (80) 510 (42) 42,598 Closed-end Funds 11,271 1 176 (51) 11,397 Total AUM $87,509 ($88) $1,344 ($150) $88,615 About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore. View original content: SOURCE Cohen & Steers, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
41 minutes ago
- Business Upturn
MUSE Microscopy, Inc. Launches Veterinary Digital Pathology with the First-of-Its-Kind Tissue-to-Direct Digital Imaging for the Veterinary Market
IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) — MUSE Microscopy, Inc., a pioneer in digital pathology innovation, today announced the formation of MUSE Veterinary Digital Pathology, LLC, a wholly-owned subsidiary focused on transforming pathology through point-of-care service. This initiative aims to provide same-day results for tissue biopsies. This new service will provide the gold standard of patient care allowing veterinarians to deliver pet parents with diagnosis, prognosis, and treatment plans efficiently using the SmartPath MUSE Technology™ (SmartPath)* Platform. The strategic move signifies MUSE's formal entry into the veterinary health market, bringing point-of-care and real-time diagnostic imaging to specialty, emergency, and family veterinary practices nationwide. Utilizing the unique capabilities of SmartPath for rapid, non-destructive tissue imaging, MUSE Veterinary Digital Pathology empowers veterinarians to make real-time treatment decisions, marking a significant innovation in tissue pathology in the past century. Matthew Nunez, CEO of MUSE Microscopy, will lead MUSE Veterinary Digital Pathology supported by a seasoned executive, Darin Nelson, who has a proven track record in building and scaling veterinary diagnostic companies. He acquired more than 800 animal hospitals for both VCA and Thrive Pet Healthcare and helped pet insurer Trupanion go public. Darin will join the company as President. Dr. Jeffrey Edwards, DVM, MPH, MRVCS, DAVCP, a clinical leader in veterinary diagnostics in his storied career, has been appointed as Chief Medical Officer overseeing the anatomic pathology team and the translational adoption of our innovative technology in veterinary practices nationwide.. Advertisement 'This launch represents a natural and strategic expansion of our technology platform,' stated Matthew Nunez. 'The veterinary sector is primed for innovation in diagnostic speed and precision. With MUSE Veterinary Digital Pathology, we are delivering state-of-the-art digital pathology directly to the point-of-care, empowering veterinarians to deliver faster diagnoses, reduce unnecessary delays, and elevate patient care.' MUSE Veterinary Digital Pathology will initially target specialty and emergency practices and large general practices, expected to commence in Q4 2025. The platform's intraoperative capabilities, same day results, and SmartPath's tissue-to-digital imaging will provide real-time surgical margin assessments and tissue diagnostics without reliance on current conventional slide-based workflows. 'This is about putting powerful diagnostic tools directly into the hands of veterinarians when and where they need them most,' stated Darin Nelson. 'Our goal is to enable faster decision-making, minimize wait times, and ultimately improve clinical outcomes for animal patients.' 'Veterinary medicine is long overdue for this level of innovation,' added Dr. Jeffrey Edwards. 'With our groundbreaking technology, we can reduce the delay in receiving biopsy results currently requiring couriers and 3-7 days down to same day diagnosis, changing the entire dynamic of medical management and clinical decision making as well as alleviated owner anxiety of waiting.' MUSE Veterinary Digital Pathology will operate independently while leveraging MUSE Microscopy's existing infrastructure, regulatory framework, personnel, and proprietary imaging technologies. The company anticipates additional announcements in the coming months, including pilot partnerships and distribution opportunities across the U.S. and internationally. About MUSE Microscopy, Inc. MUSE Microscopy is a company that specializes in the application of Microscopy with Ultraviolet Surface Excitation (MUSE). We have developed a MUSE-enabled imaging system for diagnostic assistance in pathology, and research applications. Our commercial product, SmartPath MUSE Technology™ (SmartPath)*, is a slide-free direct-to-digital imaging platform that aims to transform the patient's experience and provide healthcare professionals with quick diagnostic information through digital imaging. To learn more, you can visit their website at or find them on social media platforms such as Twitter, Facebook, and LinkedIn. *Pending FDA approval. Limits on Accuracy This press release is intended to provide information about MUSE Microscopy, Inc.'s research and potential product. Information is believed to be accurate at the time it is created. However, like any printed material, information may become outdated over time. Information may contain technical inaccuracies or typographical errors. Information may be changed or updated without notice. There may also be improvements or changes in the products and services described in this press release at any time without notice. It is important that you rely on the advice of an appropriate professional. Nothing contained in any presentation is to be construed as medical, legal, investment, financial, or other advice. This information is not intended to be a substitute for such advice. MUSE Microscopy, Inc., does not endorse any specific techniques or methods of treatment. Individuals are advised to consult their health care professionals for full information about the potential adverse reactions from use of the medical technologies discussed in this press release. We will use reasonable efforts to include accurate and up-to-date information on the website, but MUSE Microscopy, Inc. makes no warranties or representations as to its accuracy. Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans, prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. MEDIA CONTACT: Matthew Nuñez Tel: 949.813.6121 [email protected] Source: MUSE Microscopy, Inc. Join the Evolution. Embrace the Future. #DigitalPathology #SlideFreeRevolution #SmartPathMUSE For more information about MUSE Microscopy and its innovative technologies, please visit Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
